Silas Inman

The FDA has granted a priority review designation to carfilzomib in combination with dexamethasone for patients with relapsed multiple myeloma following prior treatment with at least one therapy.

The USPSTF has issued a draft guideline recommending the use of low-dose aspirin for the prevention of colorectal cancer and cardiovascular disease in adults aged 50 to 59 years.

Trabectedin demonstrated superior disease control compared with dacarbazine in heavily pretreated patients with advanced soft tissue sarcoma.

Long-term aspirin use significantly lowered the risk of developing colorectal cancer in Lynch syndrome carriers while ameliorating the added risk associated with obesity.

A supplemental new drug application has been submitted for the BTK inhibitor ibrutinib (Imbruvica) as a therapy for treatment-naive patients with chronic lymphocytic leukemia who are over the age of 65.

Treatment with the second-generation HER2/EGFR-targeted TKI neratinib resulted in a partial response and dramatic improvement in functional status for a patient with HER2-mutated breast cancer.

Coexisting driver mutations in EGFR-mutant non–small cell lung cancer could potentially contribute to primary resistance to EGFR-targeted therapy.

The FDA has granted a priority review designation to the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma.

Treatment with the PD-1 inhibitor nivolumab demonstrated a 32% reduction in the risk of death compared with docetaxel for patients with previously treated squamous non–small cell lung cancer.

Overregulation of new drug development has driven up the cost of care and resulted in significant loss of human life by delaying the approval of effective medications.

The FDA has assigned a priority review designation to daratumumab for heavily pretreated patients with multiple myeloma.

The European Commission has approved panobinostat in combination with bortezomib and dexamethasone for adult patients with relapsed/refractory multiple myeloma following prior treatment with bortezomib and an immunomodulatory agent.

The telomerase inhibitor imetelstat has shown encouraging signs of clinical activity in patients with myelofibrosis and essential thrombocythemia.

The first FDA-approved biosimilar, Zarxio, is now available for patients in the United States, following a series of lawsuits and court decisions.

The FDA has approved aprepitant capsules in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting in patients aged 12 to 17 and for those under the age of 12 who weigh at least 30 kg who are receiving chemotherapy.

The European Commission has approved eltrombopag as a treatment for adult patients with severe aplastic anemia who are refractory to immunosuppressive therapy or are heavily pretreated and not suitable for hematopoietic stem cell transplant.

ASCO has updated their clinical practice guideline for the treatment of patients with stage IV non-small cell lung cancer, placing greater emphasis on the selection of targeted therapies.

The FDA has assigned a priority review designation to the intravesical immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guerin therapy.

Patients with HER2-positive breast cancer that was ≤2 cm experienced a substantial improvement in disease-free and overall survival when treated with adjuvant trastuzumab.

Findings from a second phase II clinical trial have demonstrated impressive signs of clinical activity with the anti-CD38 monoclonal antibody daratumumab as a monotherapy for patients with heavily pretreated multiple myelom.

The alpha particle–emitting radiopharmaceutical radium-223 (Xofigo) is set to expand beyond prostate cancer, given the agent's potent efficacy and mild toxicity profile for patients with osteoblastic metastases.

Medivation has announced that it will purchase the PARP inhibitor talazoparib (BMN-673) from BioMarin Pharmaceutical for $410 million, with additional milestone and royalty payments of up to $160 million.

The FDA has approved eltrombopag as a treatment for pediatric patients with chronic immune thrombocytopenic purpura following a lack of response to other therapies or splenectomy.

The European Medicines Agency has accepted a marketing authorization application for ixazomib in combination with lenalidomide and dexamethasone for patients with relapsed/refractory multiple myeloma.

The FDA has approved the antibody-drug conjugate brentuximab vedotin as a consolidation therapy following autologous stem cell transplantation in patients with Hodgkin lymphoma who are at risk of relapse or progression.

The FDA has extended the review period for frontline nivolumab in patients with advanced melanoma by 3 months, to allow ample time to review additional data submitted by the PD-1 inhibitor's developer Bristol-Myers Squibb.

Treatment with single-agent venetoclax has met the primary endpoint of a pivotal phase II study for patients with relapsed or refractory chronic lymphocytic leukemia harboring the 17p deletion.

Frontline treatment with intraperitoneal chemotherapy is commonly underutilized for a majority of patients with optimally cytoreduced stage III ovarian cancer, despite recommendations for its use and a clear demonstration of improved overall survival.

Treatment with telotristat etiprate significantly reduced the average number of daily bowel movements compared with placebo for patients with carcinoid syndrome that was not adequately controlled with a somatostatin analog.

A new drug application has been submitted for rociletinib as a treatment for patients with EGFR T790M-positive metastatic non–small cell lung cancer following prior administration of an EGFR TKI.